ABPI

Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO

Retrieved on: 
Friday, October 27, 2023
Bank, Therapy, University of Chicago, UBS, HEC Paris, SVB Securities, Head, Alcon, Retina, Marketing, Latin honors, AMD, Organization, Acquisition, Eye, Lead, University, Health, Patient, Sports Medicine Australia, Rejuvenation, BofA Securities, University of Rouen Normandy, Growth, Business administration, Paris, Doctor of Pharmacy, Master of Business Administration, Pharmaceutical industry, Presbyopia, HSBC, Country, Biology, ABPI, Medicine, R, The arts, University of Chicago Booth School of Business, School, CFO, Management, Ophthalmology, Novartis, Aerie, Business

MELBOURNE, Australia, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that the company’s Chief Executive Officer, Dr. Megan Baldwin, will transition to Founder and Chief Innovation Officer, effective today, reflective of the company’s strategy to advance its US and global presence and commercialization strategy for sozinibercept (OPT-302).

Key Points: 
  • Concurrently, Opthea is pleased to announce the appointments of U.S.-based executives, Dr. Frederic Guerard as Chief Executive Officer and Peter Lang as Chief Financial Officer.
  • “On behalf of the Board, I am pleased to welcome Fred Guerard and Peter Lang to Opthea’s leadership team.
  • Both come to Opthea with impressive credentials to position Opthea for future growth and success,” commented Dr. Jeremy Levin, Chairman of Opthea’s Board of Directors.
  • Peter graduated with a Master of Business Administration from The University of Chicago, Booth School of Business, with High Honors.

Parenteral Drug Association and Euromed Communications release Industrial Pharmaceutical Microbiology Under New Collaboration

Retrieved on: 
Monday, September 25, 2023
FIP, Partnership, Book, Education, RPS, ABPI, Parenteral Drug Association, Multimedia, Science, PDA, EMA, Bio Products Laboratory, Publishing, Publication, Patient, Federation, Royal Pharmaceutical Society, FDA, EC, MHRA, Pharmaceutical industry

BETHESDA, Md., Sept. 25, 2023 /PRNewswire-PRWeb/ -- Parenteral Drug Association, Inc. (PDA) and based Euromed Communications today announced the publication of Industrial Pharmaceutical Microbiology: Standards & Controls (Sixth Edition), edited by Tim Sandle of Bio Products Laboratory, UK. This 700-page volume includes 25 chapters from 20 authors. Electronic copies are sold by both PDA and Euromed Communications and hardcopies exclusively by the latter company.

Key Points: 
  • BETHESDA, Md., Sept. 25, 2023 /PRNewswire-PRWeb/ -- Parenteral Drug Association, Inc. (PDA) and based Euromed Communications today announced the publication of Industrial Pharmaceutical Microbiology: Standards & Controls (Sixth Edition), edited by Tim Sandle of Bio Products Laboratory, UK.
  • Electronic copies are sold by both PDA and Euromed Communications and hardcopies exclusively by the latter company.
  • To learn more about this title and/or to purchase it, click here to the PDA Bookstore or the Euromed Communications store .
  • Over the years EC has built up close associations with various international pharmaceutical organisations such as the Royal Pharmaceutical Society (RPS), the Association of British Pharmaceutical Industries (ABPI), and the Federation of Industrial Pharmacists (FIP).

Amarin Appoints Adam Berger and Geraldine Murphy to Board of Directors

Retrieved on: 
Thursday, October 20, 2022
Decision-making, U.S. Securities and Exchange Commission, Securities Act of 1933, Cardiovascular disease, Risk, Health care, SEC, Citigroup, Growth, Review, Science, Partner, Doh, Â, Professional corporation, NASDAQ, National, Security (finance), Annual report, Wells Fargo, Company, Department, FAQ, Brother, Department of Health (Philippines), Board, Association, M&A, Director, File, GLOBE, ABPI, Record, Chief executive officer, Retirement, Leadership, Management, Pharmaceutical industry, Amarin Corporation

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Adam Berger and Geraldine Murphy as independent members of the Companys Board of Directors, effective immediately.

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Adam Berger and Geraldine Murphy as independent members of the Companys Board of Directors, effective immediately.
  • Mr. Wold-Olsen continued, On behalf of the entire Board, I also want to express our deep gratitude to Lars and Paddy for their leadership, tenure, and dedication to the Amarin Board.
  • Mr. Berger has more than three decades of experience with investment banking focused on mergers and acquisitions.
  • Ms. Murphy has a strong focus on people and organizational development which will be of significant value to Amarin and the Amarin Board.

Global Pharmaceutical Manufacturing Industry Outlook, 2027 - Cumulative & Regional Revenue Insights by Molecule Type, Drug Development Type, Formulation, Application, and Prescription Type - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 13, 2022
Health, Pharmaceutical, Association of the British Pharmaceutical Industry, Degenerative disease, ABPI, Vaccine, Diabetes, Death, Pharmaceutical industry, Access, WHO, Company, R, Eli Lilly and Company, International Diabetes Federation, Patient, COVID-19, NCD, AstraZeneca, Pfizer, IDF, EUR, Ferring Pharmaceuticals, Pressure, CAGR, World Health Organization, Research, World, Association, Cancer, Drug development, Conditional sentence, Fine chemical, Growth

The Global Pharmaceutical Manufacturing Market is expected to register a CAGR of more than 11% over the forecast period, 2022-2027.

Key Points: 
  • The Global Pharmaceutical Manufacturing Market is expected to register a CAGR of more than 11% over the forecast period, 2022-2027.
  • The COVID-19 pandemic is an unprecedented health concern and has significantly impacted the pharmaceutical manufacturing market.
  • For instance, as per the Association of the British Pharmaceutical Industry (ABPI), pharmaceutical companies continue to scale up global supply.
  • Thus, such statistics reflect that several pharmaceutical companies are expanding their manufacturing capacities in order to meet the rising demand.

SOPHiA GENETICS Announces Nomination of Jean-Michel Cosséry to Board of Directors

Retrieved on: 
Thursday, May 5, 2022
Board, Board of directors, Forward-looking statement, GE Healthcare, Professional Football Compensation Committee, Instagram, Twitter, U.S. Securities and Exchange Commission, GENETICS, Health, Rotterdam School, American Oncology Institute, Doctor of Philosophy, Sophia, Shareholder, CEO, Industry, Leadership, Multimedia, Novartis, Marketing, LinkedIn, Sale, Global marketing, MBA, ABPI, Rotterdam School of Management, Erasmus University, Software as a service, Solution, Neuroscience, Research, Sophia Genetics, Technology, Annual, Doctor of Pharmacy, Eli Lilly, IPO, Financial compensation, Therapy, Management, Immunocore, University of Paris, Serono, Pharmacology, Sanofi, Director

BOSTON and LAUSANNE, Switzerland, May 5, 2022 /PRNewswire/ --SOPHiA GENETICS (Nasdaq:SOPH), a leader in data-driven medicine, today announced the nomination of Jean-Michel Cossry to its Board of Directors.

Key Points: 
  • BOSTON and LAUSANNE, Switzerland, May 5, 2022 /PRNewswire/ --SOPHiA GENETICS (Nasdaq:SOPH), a leader in data-driven medicine, today announced the nomination of Jean-Michel Cossry to its Board of Directors.
  • The Board of Directors will propose the appointment of Mr. Cossry as a member of the Board of Directors and a member of the Compensation Committee to the Annual General Meeting of Shareholders of SOPHiA GENETICS SA, to convene on June 15, 2022.
  • "We are pleased to welcome him to SOPHiA's Board of Directors and look forward to benefiting from his leadership expertise to help accelerate our growth strategy across oncology and biopharma."
  • "SOPHiA GENETICS is a leader and innovator in a field which has the potential to change the way healthcare is delivered, an industry with an incredible growth opportunity ahead," said Jean-Michel Cossry.

SOPHiA GENETICS Announces Nomination of Jean-Michel Cosséry to Board of Directors

Retrieved on: 
Thursday, May 5, 2022
Board, Board of directors, Forward-looking statement, GE Healthcare, Professional Football Compensation Committee, Instagram, Twitter, U.S. Securities and Exchange Commission, GENETICS, Health, Rotterdam School, American Oncology Institute, Doctor of Philosophy, Sophia, Shareholder, CEO, Industry, Leadership, Novartis, Marketing, LinkedIn, Sale, Global marketing, MBA, ABPI, Rotterdam School of Management, Erasmus University, Software as a service, Solution, Neuroscience, Research, Sophia Genetics, Technology, Annual, Doctor of Pharmacy, Eli Lilly, IPO, Financial compensation, Therapy, Management, Immunocore, University of Paris, Serono, Pharmacology, Sanofi, Director

BOSTON and LAUSANNE, Switzerland, May 5, 2022 /PRNewswire/ --SOPHiA GENETICS (Nasdaq:SOPH), a leader in data-driven medicine, today announced the nomination of Jean-Michel Cossry to its Board of Directors.

Key Points: 
  • BOSTON and LAUSANNE, Switzerland, May 5, 2022 /PRNewswire/ --SOPHiA GENETICS (Nasdaq:SOPH), a leader in data-driven medicine, today announced the nomination of Jean-Michel Cossry to its Board of Directors.
  • The Board of Directors will propose the appointment of Mr. Cossry as a member of the Board of Directors and a member of the Compensation Committee to the Annual General Meeting of Shareholders of SOPHiA GENETICS SA, to convene on June 15, 2022.
  • "We are pleased to welcome him to SOPHiA's Board of Directors and look forward to benefiting from his leadership expertise to help accelerate our growth strategy across oncology and biopharma."
  • "SOPHiA GENETICS is a leader and innovator in a field which has the potential to change the way healthcare is delivered, an industry with an incredible growth opportunity ahead," said Jean-Michel Cossry.

First of its Kind Coalition Sees Health Industry, Professional Bodies and Experts Come Together to Holistically Tackle ‘Hidden Pandemic’ of Antibiotic Resistant Infections

Retrieved on: 
Monday, February 14, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Hospitals, Patient, 1969 White Paper, Genetically modified bacteria, Infection, NHS, Government, Science, AMR, Global health, Pandemic, ABPI, Society, Association of the British Pharmaceutical Industry, Outline, Awareness, Goal, Antimicrobial chemotherapy, Medtech, Neglected tropical diseases, Roche Diagnostics, AMS, Pfizer, Partnership, IMC, Policy, Pharmaceutical industry, Public health, Microbiology, White paper, Accidental Death and Disability: The Neglected Disease of Modern Society, Association, Diagnosis, COVID-19, Vaccination, British Society for Antimicrobial Chemotherapy, Industry, Antimicrobial stewardship, Vaccine, Pfizer UK, the Infection Management Coalition (IMC), antimicrobial stewardship (AMS), antimicrobial resistance (AMR), THE INFECTION MANAGEMENT COALITION (IMC), ANTIMICROBIAL STEWARDSHIP (AMS), ANTIMICROBIAL RESISTANCE (AMR)

Antimicrobial resistance is a growing challenge and an existential threat that we must overcome, says Dr David Jenkins, President of the British Society for Antimicrobial Chemotherapy.

Key Points: 
  • Antimicrobial resistance is a growing challenge and an existential threat that we must overcome, says Dr David Jenkins, President of the British Society for Antimicrobial Chemotherapy.
  • We are encouraged to see for the first time, a diverse range of sectors and industries come together in partnership through this Coalition, to address the critical issue of infection management.
  • We are a wide-ranging coalition of opinion leaders, health professionals and their societies, the scientific community and industry.
  • Given our shared and common goal with the Governments commitments to address this, a unified approach is required.

Ondine Biomedical appoints new Board of Directors

Retrieved on: 
Tuesday, December 7, 2021
MSD, Merck, Solution, Public policy, Supervisory board, GLOBE, Medical Affairs Bureau, House, Audit committee, COO, CureVac, Reckitt, Board of directors, Eyeish, McCarthy, IPO, CEO, Medtech, RCGP, Therapy, ABPI, Partnership, McKesson Europe, EMEA, Board, Canadian House of Commons Page Program, Subclinical infection, Merck Sharp & Dohme Federal Credit Union, Microsoft Research, Entrepreneurship, NHS, NHS Confederation, Health Foundation, Pharmacia, The Advisory Board Company, Senior, Telefónica, Upjohn, Elanco, Partner, Legacy Fighting Alliance in 2018, CIPFA, Nose, Doctor of Philosophy, Merck & Co., Hospital, Silence Therapeutics, Acquisition, CFO, Commons, Management, Pharmaceutical industry

Vancouver, Canada, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Canadian life sciences company, Ondine Biomedical, has appointed a new Board of Directors with considerable medtech and pharma expertise following its listing on the London AIM market.

Key Points: 
  • Vancouver, Canada, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Canadian life sciences company, Ondine Biomedical, has appointed a new Board of Directors with considerable medtech and pharma expertise following its listing on the London AIM market.
  • Carolyn Cross, Founder and CEO of Ondine, and Nicolas G. Loebel, PhD, President and Chief Technology Officer, will remain on the Board.
  • Ondine is at the forefront of development of photodisinfection-based therapies to address the large and growing need for solutions to a broad spectrum infections, including drug-resistant strains.
  • Steriwave has been deployed in Canadian hospitals for over ten years and has contributed to significant reductions in infection rates.

Accuray CyberKnife® Robotic Radiotherapy Platform Could Significantly Improve Survival in Early-Stage Breast Cancer Patients

Retrieved on: 
Monday, October 25, 2021
Safety, Program, Neoplasm, Twitter, U.S. Securities and Exchange Commission, Dalhousie University, Radiation, Survival rate, RWE, NCI, North American Association of Central Cancer Registries, Cyberknife, Erasmus, Incidence, Association, Survival, BEIR, Security (finance), Private Securities Litigation Reform Act, Intelligence, SLC Agrícola, Literature, Pooled analysis, Risk, Panacea Medical Technologies, Real, Synchrony, International Institute for Population Sciences, SLC, Breast cancer, SEC, ABPI, FABS, Surveillance, Erasmus MC, SRP, Population, Frontiers, Technology, LinkedIn, Annual report, Lung, Database, Patient, NASDAQ, YouTube, SEER, Time, Forward-looking statement, Mortality, Medical imaging, Pharmaceutical industry

SUNNYVALE, Calif., Oct. 25, 2021 /PRNewswire/ --Accuray Incorporated(NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast irradiation (APBI) delivered using the Accuray CyberKnife robotic radiotherapy platform.

Key Points: 
  • SUNNYVALE, Calif., Oct. 25, 2021 /PRNewswire/ --Accuray Incorporated(NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast irradiation (APBI) delivered using the Accuray CyberKnife robotic radiotherapy platform.
  • The addition of radiotherapy can extend survival that may be offset by the development of a secondary cancer like lung tumors many years following treatment.
  • This study reinforces the unparalleled accuracy of a 4-like robotic CyberKnife platform and shows its tremendous potential as a treatment for early-stage breast cancer," said Suzanne Winter, president at Accuray.
  • Breast cancer stage distribution and number of new cases were obtained from the North American Association of Central Cancer Registries (NAACCR).

Appointment of Professor Trevor M Jones, CBE FMedSci, as Non-Executive Director

Retrieved on: 
Monday, September 20, 2021
Ascension, Pharmacy, Haemophilia, Federalisation of the European Union, OTC, Quality assurance, Board of directors, Research and development, IMI, GlaxoSmithKline, APS, Board, Osteoarthritis, ABPI, CBE, COVID-19, Apotex Inc v Wellcome Foundation Ltd, Academy of Pharmaceutical Sciences, Pariyaram, Government, Industry, Academy, Management, Pharmaceutical industry

Appointment of Professor Trevor M Jones, CBE FMedSci, as Non-Executive Director

Key Points: 
  • Appointment of Professor Trevor M Jones, CBE FMedSci, as Non-Executive Director
    LONDON, September 20, 2021 Ascension Healthcare plc (Ascension or the Company), a clinical-stage pharmaceutical company focused on developing and commercialising innovative therapies for haemophilia and osteoarthritis is pleased to announce the appointment of Prof. Trevor M Jones, CBE FMedSci, as a Non-Executive Director to the Board with immediate effect.
  • He oversaw a department of over 2,500 staff covering all scientific, technical, and medical specialties, as well as Quality Assurance and Patents.
  • Biresh Roy, Chief Executive Officer of Ascension said: We are delighted to welcome Trevor to our Board of Directors.
  • Prof. Trevor Jones, CBE FMedSci, Non-Executive Director at Ascension, added: I have known Biresh for several years and have followed with interest the work Ascension are doing.